New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. - Wikidata - awgldk - TriplyDB

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q38576015

about

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer.PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.Impact of in vitro chemosensitivity test-guided platinum-based adjuvant chemotherapy on the surgical outcomes of patients with p-stage IIIA non-small cell lung cancer that underwent complete resection.Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC).Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors.Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.

P2860

Q26778500-CC9A676B-D4CA-4F8A-B9C3-E0753DCA0B85 Q36096398-51E88058-1A60-44BB-AADD-690C0AAB6EBA Q37696089-A187B6F9-31AC-4306-BD3D-66064E7D1AE5 Q37708899-28F77181-C82E-4D54-A632-5E30FA123CF8 Q38622807-22FCFD53-9940-4095-BE4E-3267FD9937A0 Q40185703-F8A7EB04-4F6E-4C9C-AFF7-6225BEE9AD53 Q41341776-97C20059-0CCE-4FD2-9C92-39B3A9092428 Q54123036-4B78AC39-E9A1-41D9-A069-12275CE7171E

P2860

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q38576015

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

@en

type

label

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

@en

prefLabel

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

@en

P1433

Q38576015-FC626B16-6881-40A0-B3D7-8493DBAC6C9E

P1476

Q38576015-F5249199-EC29-4060-A8F1-FD3F650A851F

P2093

Q38576015-8B03A590-C64A-4979-AC39-7E9B6A46A938

Q38576015-BECA0F09-2534-492E-AE68-B0F9E926A8CE

P2860

Q38576015-06161137-34AD-44C1-959D-2552FEB781B9

Q38576015-0B324016-4836-4926-8864-D8A4818F5984

Q38576015-12CACC8F-CAD3-49BB-B6C8-7D7695780B80

Q38576015-134D03ED-A595-4F7F-BE1D-22098DC5EDB4

Q38576015-21D29954-5BF6-48BC-B64E-149BA86434A5

Q38576015-222B6E67-0E07-49BA-B94C-577949DC90B1

Q38576015-241D0467-DC1D-4955-A9EB-888E27DC9710

Q38576015-2BCA24D6-811D-4542-8CB7-68131E1A0791

Q38576015-2C36C32C-A3B1-4A8E-9F11-873FD8F8D036

Q38576015-2CFCF226-6ECB-42AB-AF95-2C9ACE87992A

P2888

Q38576015-FD9FE4EA-31E0-418F-8799-0F11156D00AD

P304

Q38576015-2D7F71EA-2D67-4F7F-982A-16920CACAA40

P31

Q38576015-9772A2AD-05C0-419B-99B7-1EF294E10A64

P356

Q38576015-BE581C53-BA55-4457-B5D1-C22C0FC60A13

P433

Q38576015-3C9703A8-0205-4DB6-8D74-9A6A571D419D

P478

Q38576015-9944AC18-12AC-449E-B1EA-C11CCA9B3114

P577

Q38576015-89F23783-87EE-4205-A40F-28AF8674F848

P6179

Q38576015-F00E3377-B06D-46D0-B3C3-9DC46BE20CA2

P698

Q38576015-0DA5BDA4-45B2-450E-94CC-CB364B40A656

P356

S11864-015-0367-Z

P1433

Current Treatment Options in Oncology

P1476

New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer.

@en

P2093

Benjamin Solomon

http://www.w3.org/2001/XMLSchema#string

Laird Cameron

http://www.w3.org/2001/XMLSchema#string

P2860

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

P2888

s11864-015-0367-z

P304

49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-015-0367-Z

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003468520

http://www.w3.org/2001/XMLSchema#string

P698

26318457

http://www.w3.org/2001/XMLSchema#string